|
Virtual Meetings 2022
Meet The Professor: Current and Future Management of Chronic Lymphocytic LeukemiaFor an up-to-date schedule of upcoming sessions in this series, please click here. PARTICIPATING FACULTY
Jennifer R Brown, MD, PhD CLL Center Director and Institute Physician Dana-Farber Cancer Institute Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology Harvard Medical School Boston, Massachusetts Peter Hillmen, MB ChB, PhD Professor of Experimental Haematology University of Leeds Honorary Consultant Haematologist Leeds Teaching Hospitals NHS Trust Leeds, United Kingdom Susan O’Brien, MD Professor, Division of Hematology/Oncology School of Medicine UCI Chao Family Comprehensive Cancer Center Orange, California Kerry Rogers, MD Assistant Professor in the Division of Hematology The Ohio State University Columbus, Ohio Jeff Sharman, MD Medical Director of Hematology Research US Oncology Network Willamette Valley Cancer Institute and Research Center Eugene, Oregon William G Wierda, MD, PhD DB Lane Cancer Research Distinguished Professor Section Chief, Chronic Lymphocytic Leukemia Center Medical Director Department of Leukemia, Division of Cancer Medicine Executive Medical Director, Inpatient Medical Services The University of Texas MD Anderson Cancer Center Houston, Texas SERIES MODERATOR Neil Love, MD Research To Practice These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC. Agenda
MODULE 1: Optimizing the Selection of Therapy for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL) MODULE 2: Toxicity and Tolerability Considerations with the Use of BTK and Bcl-2 Inhibitors for CLL MODULE 3: Selection and Sequencing of Therapy for Relapsed/Refractory CLL MODULE 4: Novel Approaches Under Investigation in CLL
Target Audience
CE Credit Form American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Brown — Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, BeiGene Ltd, Bristol-Myers Squibb Company, Catapult Therapeutics, Genentech, a member of the Roche Group, HUTCHMED, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Lilly, MEI Pharma Inc, MorphoSys, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Rigel Pharmaceuticals Inc; Contracted Research: Gilead Sciences Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Secura Bio, Sun Pharmaceutical Industries Ltd, TG Therapeutics Inc. Prof Hillmen — Advisory Committee: AbbVie Inc, Apellis, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Janssen Biotech Inc, Sobi; Consulting Agreements: AbbVie Inc, Apellis, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Sobi; Contracted Research: AbbVie Inc, Apellis, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc; Speakers Bureau: AbbVie Inc, Apellis, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Janssen Biotech Inc, Roche Laboratories Inc, Sobi. Dr O’Brien — Consulting Agreements: AbbVie Inc, Alexion Pharmaceuticals, Amgen Inc, Aptose Biosciences Inc, Astellas, AstraZeneca Pharmaceuticals LP, Autolus, Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Juno Therapeutics, a Celgene Company, Lilly, MEI Pharma Inc, Merck, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, TG Therapeutics Inc, Vaniam Group, Verastem Inc, Vida Ventures; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Alliance Pharma, BeiGene Ltd, Caribou Biosciences Inc, Gilead Sciences Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mustang Bio, Nurix Therapeutics Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, TG Therapeutics Inc. Dr Rogers — Advisory Committee: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Innate Pharma, Pharmacyclics LLC, an AbbVie Company; Consulting Agreement: Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Novartis, Vincerx Pharma. Dr Sharman — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck, TG Therapeutics Inc; Research Funding: Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Merck, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc. Dr Wierda — Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Cyclacel Pharmaceuticals Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miragen, Novartis, Oncternal Therapeutics, Pharmacyclics LLC, an AbbVie Company, Sunesis Pharmaceuticals Inc, Xencor.SURVEY PARTICIPANT — Matthew S Davids, MD, MMSc — Advisory Committee: AbbVie Inc, Adaptive Biotechnologies Corporation, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc, Verastem Inc, Zentalis Pharmaceuticals; Contracted Research: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, MEI Pharma Inc, Novartis, Pharmacyclics LLC, an AbbVie Company, Surface Oncology, TG Therapeutics Inc, Verastem Inc. SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.Supporters These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC. |